<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864029</url>
  </required_header>
  <id_info>
    <org_study_id>BMN 162-504</org_study_id>
    <nct_id>NCT03864029</nct_id>
  </id_info>
  <brief_title>Retrospective Observational Safety Effectiveness With Kuvan in hpA</brief_title>
  <acronym>ROSEKA</acronym>
  <official_title>An Observational Study Research to Collect the Effectiveness and Safety Data of KUVAN® Retrospectively in Chinese Subjects With Hyperphenylalaninemia (HPA) Caused by Tetrahydrobiopterin (BH4) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective study to collect the effectiveness and safety data of the past treatment with
      KUVAN in Chinese patients with HPA caused by BH4 deficiency. The data was collected from
      relevant past medical history and past clinical and safety assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis on BH4 deficiency based on medical history - laboratory testing results indicating sub-type (% in each sub-type) • Incidents and severity of AE reported (% of incident / % of each severity)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective KUVAN treatment history - dose (mg/kg/day),</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective KUVAN treatment history - length of exposure (days)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective Baseline Phe concentration ≥ 450 μmol/L - laboratory testing results (μmol/L)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with AE reported (% of patient with AE reported)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidents and severity of AE reported (% of incident / % of each severity)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective blood Phe level as indicated in laboratory testing results (μmol/L)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective body height as indicated in medical note (cm)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective body weight as indicated in medical note (kg)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective occipital / frontal circumferences as indicated in medical note (cm)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective intelligence development status via China local standard development assessment method (score)</measure>
    <time_frame>2010-2015</time_frame>
  </primary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Tetrahydrobiopterin Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUVAN</intervention_name>
    <description>retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN</description>
    <other_name>Diagnostic Tests</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese subjects with HPA caused by BH4 deficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent (unless exemption of obtaining consent is
             obtained as per local regulation). Assent (if required defined by local regulation and
             requirement) should also be obtained from the subject and the legal authorized
             representative.

          -  Diagnosed with BH4 deficiency per local practice.

          -  KUVAN® was taken at least 1 dose to treat HPA caused by BH4 deficiency during the
             period of observation.

          -  Baseline Phe concentration ≥ 450 µmol/L

        Exclusion Criteria:

          -  Subject diagnosed to have Phenylketonuria (PKU)

          -  Has any condition that, in the view of the Investigator, the medical record of the
             subject in the duration of observation is not reliable, or not accessible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

